Ultralow Dose of Nivolumab Offers Huge Cost Savings

A clinical trial from India raises the possibility of huge cost savings by using ultralow immunotherapy doses in the treatment of head and neck cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/987096?src=rss